RxDoctor Payments Data

Vinh Cam, MD

Nephrology · Torrance, CANPI 1144243908

Payments from drug & device makers

$84,838in general payments, 2019–2025

Across 1,093 payments — averaging $77.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$22K
  • Lilly USA, LLC$14K
  • Travere Therapeutics, Inc.$13K
  • AstraZeneca$12K
  • Vifor Pharma, Inc.$7K
  • Amgen$4K
  • plus $12K from 38 others

What the payments were for

  • Consulting fees$4,0135%
  • Speaking & faculty fees$56,77367%
  • Travel & lodging$3,3804%
  • Food & beverage$20,37924%
  • Education$2940%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,838 in reported general payments places this provider in the 85th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$529,953
Medicare patients
635
Services billed
3,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol512$467,406
LupkynisVoclosporin11$160,062
JardianceEmpagliflozin167$148,412
KerendiaFinerenone93$139,114
XphozahTenapanor Hcl32$108,133
VeltassaPatiromer Calcium Sorbitex101$102,495
EliquisApixaban84$78,358
JanuviaSitagliptin Phosphate48$61,445
OzempicSemaglutide47$47,293
VelphoroSucroferric Oxyhydroxide12$41,360
EntrestoSacubitril/Valsartan31$41,105
Repatha SureclickEvolocumab42$32,850
RybelsusSemaglutide12$30,730
ProcritEpoetin Alfa36$28,719
Cinacalcet Hcl77$26,472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$11,639$489,587540 claims
Aurinia Pharma U.S., Inc.Lupkynis$1,117$160,06211 claims
Boehringer IngelheimJardiance$22,295$148,412167 claims
BayerKerendia$1,210$139,11493 claims
PfizerEliquis, Retacrit$66$91,897124 claims
Novo NordiskOzempic, Rybelsus$976$78,02359 claims
Fresenius USA Marketing, Inc.Velphoro$529$41,36012 claims
NovartisEntresto$824$41,10531 claims
Johnson & JohnsonProcrit$168$28,71936 claims
OPKO Pharmaceuticals, LLCRayaldee$724$22,70319 claims
Akebia Therapeutics IncAuryxia$926$20,34511 claims
ANI Pharmaceuticals, Inc.Valsartan$303$6,678271 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,341 nephrology providers in California.

Other nephrology in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →